Perrigo Receives Final Approval from FDA for Generic Version of Sanctura XR; FDA Approves Two Skin Cancer Treatments for GlaxoSmithKline Print E-mail
By Staff and Wire Reports   
Wednesday, 29 May 2013 19:09
Below is a look at some of the headlines for companies that made news in the healthcare sector on May 29, 2013. Perrigo Company (Nasdaq: PRGO) announced it has received final approval for the generic version of Sanctura XR®. Perrigo had previously prevailed in litigation at both the district and appellate levels. The product has begun shipping immediately.

Sanctura XR® (Trospium Chloride Extended-release Capsules, 60 mg), is a once-daily medication for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency and has annual sales of approximately $54 million, as measured by Symphony Health Solutions.

======

GlaxoSmithKline (NYSE: GSK) won approval for two drugs to treat advanced skin cancer that are accompanied by diagnostic tests to help target the treatments. The Food and Drug Administration approved Tafinlar and Mekinist for patients with melanoma, the most dangerous form of skin cancer, that has spread or can't be surgically removed, the agency said today in a statement.

Also Wednesday:


Accelerating success in the healthcare market, Ingram Micro Inc. (NYSE: IM) today announced a new series of healthcare-focused, web-based training and education modules designed specifically for use by its channel partners.

Anacor Pharmaceuticals (NASDAQ:ANAC)
announced today that it has successfully completed its pre-NDA (New Drug Application) communications with the Food and Drug Administration (FDA) related to tavaborole, its drug candidate for the topical treatment of onychomycosis. In its pre-NDA communications, Anacor achieved concurrence from the FDA on the content and format of the proposed NDA for tavaborole including required data related to safety, efficacy, manufacturing and packaging.

BioRestorative Therapies, Inc.(OTC BB: BRTX)
, a life sciences company focused on developing stem cell based cellular therapies for various personal medical applications, today announced that it has developed a human cellular-derived extract that, per initial in vitrostudies, when applied to skin cells, appears to cause a significant increase in collagen and fibronectin production (proteins that are essential for combating the aging of skin).

Belmont Global Research announced today that it had instituted initial coverage of Capital Group Holdings, Inc. (OTCQB: CGHC), a fully reporting company that operates 7 urgent care clinics in the Phoenix, Arizona metropolitan area under the OneHealth and Alliance brands which it acquired on September 3, 2012.

ChromaDex Corporation® (OTCBB: CDXC)
("ChromaDex" or the "Company"), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries, announced today the launch of NIAGEN™, its novel, patented, branded nicotinamide riboside (NR).

Decision Diagnostics Corp. (OTCBB: DECN)
, the exclusive worldwide sales, service and regulatory processes agent for the Shasta GenStrip™, the Green Test Strip, specifically designed to work with the Johnson & Johnson's (NYSE: JNJ) LifeScan family of glucose testing meters, announced today that the company and its subsidiary PharmaTech Solutions, Inc. have launched a strategically packaged version of the Shasta GenStrip™ for sale to companies who service the "direct to patient" fulfillment (mail order and durable medical goods) channels.

Dyadic International, Inc. (OTC Pink: DYAI)
, announced today that its President and CEO, Mark Emalfarb, will present at the World Biotechnology Congress 2013 in Boston, Massachusetts and the BIO World Congress on Industrial Biotech in Montreal, Canada.

iBio, Inc. (NYSE MKT: IBIO)
today announced that a patent to increase influenza vaccine performance through the use of iBio's proprietary iBioModulator fusion protein technology has been allowed in China.

Imaging3™, Inc. (PINKSHEETS: IMGGQ)
, developer of a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time, announced today that on Tuesday May 21st and Wednesday May 22nd, 2013 the US Central District Bankruptcy Court held a plan confirmation hearing and confirmed the company's plan of reorganization.

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
management provided a new corporate presentation today at the Deutsche Bank 38th Annual dbAccess Health Care Conference in Boston.

The Medicines Company (NASDAQ: MDCO)
is scheduled to present at the Jefferies 2013 Global Healthcare Conference on Tuesday, June 4th at 8:30 AM Eastern Time.

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB)
, a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that Thomas Tulip, President and Chief Business Officer, will participate at the Jefferies 2013 Global Healthcare Conference on June 3-6, 2013 at the Grand Hyatt in New York City, NY.

Nordion Inc. (TSX: NDN; NYSE: NDZ)
, a leading provider of products and services to the global health science market, today announced that the Company is scheduled to report its second quarter 2013 financial results after markets close on June 5, 2013.

Nuvilex, Inc. (OTCQB: NVLX)
and its medical marijuana subsidiary, Medical Marijuana Sciences, Inc., may have just found a way to work side by side in an area of study where the parent company is already engaged.

Ohr Pharmaceutical (OTCQB: OHRP)
, a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced that Dr. Irach Taraporewala, CEO, will present a corporate overview and business update at the second annual Marcum MicroCap Conference on Thursday, May 30, 2013 at 11:00 am ET.

Oncothyreon Inc. (Nasdaq: ONTY)
announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will present at the Jefferies 2013 Global Healthcare Conference in New York on Wednesday, June 5, 2013 at 3 p.m. Eastern.

Puma Biotechnology, Inc. (NYSE: PBYI)
, a development stage biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will present an overview of the Company at 12:30 p.m. EDT on Thursday, June 6, at the Jefferies 2013 Global Healthcare Conference.

QuickLabel Systems, a business unit of Astro-Med, Inc. (NASDAQ: ALOT), has announced a marketing agreement with Innovatum by which they will actively promote one another's products.

Simulations Plus, Inc. (NASDAQ: SLP)
, a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that it has released Version 6.5 of its best-in-class ADMET Predictor™ software program for the prediction of molecular properties from structure.

Titan Medical Inc. (TSX VENTURE:TMD) (OTCQX:TITXF)
announced today it has retained the services of CPHS Consulting Inc. ("CPHS") to provide strategic investor relations and financial communications services.

Vycor Medical, Inc. ("Vycor") (OTCBB: VYCO)
, a medical device company with a suite of FDA cleared products, announced that U.S. patent #12/545719, which relates to its ViewSite™ Brain Access System ("VBAS"), has been issued.

Zalicus Inc. (Nasdaq Capital Market: ZLCS)
a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that Zalicus management will present at the Jefferies 2013 Global Healthcare Conference at 2:30 p.m. ET on Wednesday, June 5, 2013 at the Grand Hyatt in New York.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter